• Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel
Press Releases

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

May 30, 2023

  • A type of artificial intelligence (AI), Deep Learning (DL) technology can advance medical imaging capabilities by providing more robust, accurate, and data-driven information as well as support more efficient workflows and exams
  • Precision DL for PET/CT is the latest addition to GE HealthCare’s Effortless Recon DL portfolio of deep learning-based solutions – which also includes AIR Recon DL for MRI, TrueFidelity for CT, and Helix DL for X-ray – to significantly improve image quality and help better inform clinical decision-making for improved patient outcomes
     

CHICAGO — GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratio1, contrast recovery1, and quantitative accuracy2. The AI-based technology is available on the company’s fastest-ever-selling PET/CT3, Omni Legend, which already boasts more than two times the sensitivity of prior digital scanners4, enabling faster scan times5 and impressive small lesion detectability6.

 

Together, the availability of Precision DL with Omni Legend’s ultra-high sensitivity, third generation digital detector technology marks a new era for PET/CT performance and outcomes, transitioning from ToF technology to the next generation of PET/CT performance and enabling clinicians to decode coincidence events at exceptionally fine resolutions for informed diagnoses and treatment planning.

 

 “We can’t treat what we don’t see, which is why we require precise image quality to help diagnose, plan treatment for, and monitor disease,” explains Prof. Flavio Forrer, MD, PhD,  Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. Gallen in Switzerland8. “Precision DL enhances image quality – enabling us to spot small lesions, including on images obtained with very low dose injections and short bedtimes, to potentially start treatment and monitoring early, which might result in improved patient outcomes. Additionally, Omni Legend offers a streamlined, simple solution that helps enable technologists to increase efficiency, enhance patient care, and reduce potential radiation exposure to medical staff7.”

 

Medical imaging is a crucial tool for diagnosing disease, identifying a course of treatment, and determining whether therapy is successful for millions of patients around the world. Image quality matters – to the clinician and the patient – making the difference between finding a small lesion early or in its later stages, potentially affecting patient outcomes and disease management. For this reason, clinicians are increasingly adopting AI-based solutions for enhanced image quality compared to that of standard care.

 

A subset of AI and machine learning, deep learning utilizes deep neural networks, which consist of layers of mathematical equations and millions of connections and parameters that are trained and strengthened based on the desired output. In doing so, deep learning is a significant leap forward in efficacy compared to previous processes that require more human intervention, handling complex models and vast numbers of parameters with ease to help provide clinicians the time and insights they need to more confidently diagnose and care for patients.

 

“One of the main advantages of moving fully into the future of AI and deep learning is making state-of-the-art imaging accessible to more practices, across more care areas than ever before,” shares Jan Makela, President & CEO, Imaging, GE HealthCare. “Clinicians are seeing the value of applying deep learning  technology to enhance image quality with our multi-modality family of Effortless Recon DL applications, which already includes AIR Recon DL for MR, TrueFidelity for CT, and Helix DL for X-ray. Now we are proud to add Precision DL for PET/CT, enabling more precise and personalized care across healthcare systems’ imaging departments.”

 

More than a new imaging processing technique, Precision DL was engineered with a sophisticated deep neural network trained on thousands of images created with multiple reconstruction methods, including ToF reconstruction, to provide the image quality performance benefits typically associated with hardware-based ToF reconstruction, such as improved contrast-to-noise ratio and contrast recovery1.

 

Precision DL processes patient images for enhanced image quality, including:

 

  • 11% improvement on average in contrast recovery1,
  • 23% improvement on average in contrast-to-noise ratio1,
  • 42% increase on average in small, low contrast lesion detectability8, and
  • 14% improvement feature quantification accuracy2.

 

Altogether, a study published in the European Journal of  Nuclear Medicine and Molecular Imaging, demonstrated improvement in feature quantitation, overall image sharpness, and overall diagnostic value, particularly in terms of lesion detectability and diagnostic confidence of PET/CT images reconstructed without ToF using deep learning models trained for ToF image enhancement9.

 

GE HealthCare’s deep-learning-enabled software is revolutionizing image acquisition and reconstruction in MR, CT, X-ray and now PET/CT,  empowering clinicians and helping improve patient outcomes.

 

For more information about GE HealthCare’s Precision DL, Omni Legend PET/CT, or Effortless Workflow DL, please visit gehealthcare.com.

 

###

  1. Precision DL with Omni Legend 32cm data improves Contrast Recovery (CR) by 11% on average and Contrast-to-Noise Ratio (CNR) by average of 23% as compared to non-ToF reconstruction. CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Using data from Omni Legend 32 cm, CR and CNR were measured using High Precision DL and QCHD.
  2. Precision DL with Omni Legend 32cm improves feature quantitation accuracy by 14% as compared to Discovery MI with ToF reconstruction, at comparable noise level. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Feature SUVmean from Omni Legend 32 cm with High Precision DL compared to SUVmean from Discovery MI 25 cm with QCFX.
  3. Based on orders data of GE HealthCare PET/CT systems since 2010.
  4.  Omni Legend 32 cm has up to 2.2 increase in system sensitivity as compared to Discovery MI 25 cm. Measurement follows NEMA NU 2-2018.
  5. Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing.
  6. Omni Legend 32 cm increases small lesion detectability 16% on average and up to 20%, as compared to Discovery MI 25 cm with matched scan time/injected dose, as demonstrated in phantom testing using a model observer with 4 mm lesions; average of different reconstruction methods.
  7. Not a consultant for GEHC: The statements by GE’s customers described here are based on their own opinions and on results that were achieved in the customer’s unique setting.  Since there is no “typical” hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.   
  8. Omni Legend 32cm as compared to Discovery MI 25cm, at matched scan time and injected dose. Detectability using clinical data with an inserted 8 mm diameter liver lesion of known location and 2:1 contrast using a CHO model observer, comparing SNR from Omni Legend 32 cm with QCHD and Precision DL to SNR from Discovery™ MI 25 cm with QCFX.
  9. Mehranian, A., Wollenweber, S.D., Walker, M.D. et al. Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans. Eur J of  Nucl Med Mol Imaging 49, 3740–3749 (2022). https://doi.org/10.1007/s00259-022-05824-7

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

 

Follow us on LinkedIn, X, FacebookInstagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Copy article text Link copied to clipboard

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

 

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™. 

 

Follow us on LinkedIn, FacebookInstagram, or visit our website for our latest news and perspectives

Media
Download all